Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PharmGKB summary: peginterferon-α pathway.

Pharmacogenetics and genomics - 1 Sept 2015

Shuldiner Scott R, Gong Li, Muir Andrew J, Altman Russ B, Klein Teri E

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination
Share to Hepatitis C, Chronic
Share to Interferon-alpha
Share to Interferon alpha-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferons

Share to Interleukins

Share to Polyethylene Glycols

Share to Ribavirin

Source

Open in PubMed Open full text

Identifiers

PMID: 26111151
DOI: 10.1097/FPC.0000000000000158
PMCID: PMC4757589

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PharmGKB summary: peginterferon-α pathway.PMID 26111151Read ↗

CD90.Semantic proximity Read ↗

[From ASCO and WCLC 2005 to the clinical practice: targeted therapies].Semantic proximity Read ↗

Pegylated interferon: the who, why, and howSemantic proximity Read ↗

cGAS-STING at the crossroads in cancer therapySemantic proximity Read ↗

WITHDRAWN: High-throughput preclinical screening of CD123 scFv to design 3rd generation of CAR T-cell in the treatment of BPDCN patientSemantic proximity Read ↗

PharmGKB: very important pharmacogene--HMGCR.Semantic proximity Read ↗

Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020-2023).Semantic proximity Read ↗

KRAS: Druggable at Last.Semantic proximity Read ↗

Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapy.Semantic proximity Read ↗

PharmGKB summary: Efavirenz pathway, pharmacokinetics.Semantic proximity Read ↗

ctDNA guides anti-EGFR rechallenge.Semantic proximity Read ↗

Oncolytic viral therapies – the clinical experienceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.